Crossover studies. Dantrolene after HF development mitigates VT/VF and prevents SCD
chronic contractile dysfunction
CONSTRICTION
A crossover study was designed where (i) only vehicle was administered until the endpoint i.e., week 4 (HF) (ii) DS was administered at the onset of aortic constriction until chronic contractile dysfunction is evident in the HF group (usually 3 weeks post-banding; HF+/−DS) or (iii) after HF had already developed (3 weeks post-banding; HF−/+DS group) (